Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florian Guisier

Showing results (61-70 of 90) with videos related to

Pageof 9
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 17, 2020
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018Florian Guisier, Catherine Dubos-Arvis, Florent Viñas, et al.
The Oncologist|December 26, 2024
COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancerCamille Mehlman, Aurelie Swalduz, Isabelle Monnet, et al.
Lung Cancer (Amsterdam, Netherlands)|October 15, 2023
Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC)Agathe Dehem, Julien Mazieres, Ali Chour, et al.
Targeted Oncology|November 15, 2023
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)Estelle Dhamelincourt, Renaud Descourt, Gaelle Rousseau-Bussac, et al.
Oncotarget|December 30, 2017
Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitorsSimon Baldacci, Julien Mazieres, Pascale Tomasini, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 9, 2023
Three-Year Overall Survival of Patients With Advanced Non-Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study)Chantal Decroisette, Laurent Greillier, Hubert Curcio, et al.
The Lancet. Oncology|January 21, 2019
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trialArnaud Scherpereel, Julien Mazieres, Laurent Greillier, et al.
Lung Cancer (Amsterdam, Netherlands)|July 7, 2024
Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trialOlivier Bylicki, Florian Guisier, Arnaud Scherpereel, et al.
Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutationJean Bernard Auliac, Maurice Pérol, David Planchard, et al.
Clinical Lung Cancer|September 14, 2025
Rebiopsy Feasibility and Clinical Impact on Metastatic Non-Small-Cell Lung Cancer With EGFR/ALK/ROS Oncogenic Driver Progression After Optimal Targeted Therapy: A Multicenter Real-World AnalysisAntoine Bronstein, Hubert Curcio, Isabelle Monnet, et al.
Pageof 9

Showing results (61-70 of 90) with videos related to

Sort By:
Pageof 9
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 17, 2020
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018Florian Guisier, Catherine Dubos-Arvis, Florent Viñas, et al.
The Oncologist|December 26, 2024
COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancerCamille Mehlman, Aurelie Swalduz, Isabelle Monnet, et al.
Lung Cancer (Amsterdam, Netherlands)|October 15, 2023
Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC)Agathe Dehem, Julien Mazieres, Ali Chour, et al.
Targeted Oncology|November 15, 2023
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)Estelle Dhamelincourt, Renaud Descourt, Gaelle Rousseau-Bussac, et al.
Oncotarget|December 30, 2017
Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitorsSimon Baldacci, Julien Mazieres, Pascale Tomasini, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 9, 2023
Three-Year Overall Survival of Patients With Advanced Non-Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study)Chantal Decroisette, Laurent Greillier, Hubert Curcio, et al.
The Lancet. Oncology|January 21, 2019
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trialArnaud Scherpereel, Julien Mazieres, Laurent Greillier, et al.
Lung Cancer (Amsterdam, Netherlands)|July 7, 2024
Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trialOlivier Bylicki, Florian Guisier, Arnaud Scherpereel, et al.
Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutationJean Bernard Auliac, Maurice Pérol, David Planchard, et al.
Clinical Lung Cancer|September 14, 2025
Rebiopsy Feasibility and Clinical Impact on Metastatic Non-Small-Cell Lung Cancer With EGFR/ALK/ROS Oncogenic Driver Progression After Optimal Targeted Therapy: A Multicenter Real-World AnalysisAntoine Bronstein, Hubert Curcio, Isabelle Monnet, et al.
Pageof 9